bioRxiv Science⌕ Search

Biology subjects

Suwanarusk, R.

Publications and source records attributed to Suwanarusk, R..

4 recordsLinked to original sources

A chromosome-scale Plasmodium cynomolgi Berok genome reveals a distinct subtelomeric architecture and a highly diverged primate malaria lineage

Plasmodium cynomolgi is the closest relative of P. vivax and the primary experimental model for relapsing malaria, hypnozoite biology, and blood-stage drug susceptibility. Yet existing reference genomes remain fragmented, leaving structurally complex, AT-rich regions largely unresolved. We generated a chromosome-scale genome assembly for the K4-A7 cloned line of P. cynomolgi Berok by combining Hi-C chromosome conformation capture, Oxford Nanopore long reads, PacBio, and Illumina sequencing. The assembly spans 14 chromosomes plus mitochondrial and apicoplast genomes, with only seven unplaced minor contigs, the fewest for any non-P. falciparum Plasmodium genome, and an N50 of 3.06 Mb. Critically, this hybrid strategy resolved approximately 8 Mb of extremely AT-rich (~20% GC) sequence onto chromosomes 4, 8, and 13, anchoring what were previously unplaced or absent contigs into a continuous chromosomal framework. These subtelomere-like expansions (SLEs) constitute ~26.5% of the chromosomal genome and are enriched for PIR/VIR, STP1, variable surface antigen, and methyltransferase pseudogene families. Despite low gene density, SLE-encoded genes are transcriptionally active and show stage-specific expression across the erythrocytic cycle. Integrated lifecycle transcriptomics across 7,006 genes revealed a ~54-hour erythrocytic cycle with a "just-in-time" transcriptional cascade closely resembling that of P. vivax. Phylogenomic analyses and pairwise amino acid comparisons across more than 2,600 single-copy orthologs show that Berok forms a deeply diverged P. cynomolgi lineage, suggesting a distinct subspecies. This assembly establishes a high-resolution genomic foundation for comparative malaria biology, drug discovery, and the study of subtelomeric architecture, host adaptation, and lineage boundaries in primate Plasmodium.

microbiology↗

Antiparasitic effect of peptoids against Cryptosporidium parvum

Cryptosporidiosis, caused by Cryptosporidium parvum, poses significant health risks, particularly for children and immunocompromised individuals. Current treatments are ineffective in these vulnerable groups. This study explores the antiparasitic effects of against C. parvum. Out of 14 synthetic peptidomimetics (peptoids) screened, TM9 and TM19 exhibited potent anti-cryptosporidial activity without harming host cells. These findings suggest that peptoids could be a promising new therapeutic avenue for cryptosporidiosis, warranting further investigation.

microbiology↗

Extended blood stage sensitivity profiles of Plasmodium vivax to doxycycline and tafenoquine using Plasmodium cynomolgi as a model

Testing Plasmodium vivax antimicrobial sensitivity is limited to ex vivo schizont maturation assays, which precludes determining the IC50s of delayed action antimalarials such as doxycycline. Using Plasmodium cynomolgi as a model for P. vivax, we determined the physiologically significant delayed death effect induced by doxycycline (IC50(96h), 1401 {+/-} 607 nM). As expected, IC50(96 h) to chloroquine (20.4 nM), piperaquine (12.6 {micro}M) and tafenoquine (1424 nM) were not affected by extended exposure.

microbiology↗

Comparative efficacy and safety of anti-cryptosporidial agents: An in vitro study on Nitazoxanide, HFL, KDU731, and Paromomycin against Cryptosporidium parvum

This study evaluates the in vitro effectiveness of the anti-cryptosporidial agents Nitazoxanide, Halofuginone, the pyrazolopyridine analogue KDU731, and Paromomycin in combating the significant zoonotic pathogen Cryptosporidium parvum. The study utilizes HCT-8 host cells to culture C. parvum and fluorescent microscopy and qPCR for detecting parasitic growth. The efficacy of the compounds was assessed by calculating their inhibitory concentrations against the total growth of C. parvum at 48 hours post-infection. The study further investigates the impact of these compounds on early parasitophorous vacuole formation, merozoite egress, host cell viability, and cell growth cycle. KDU731 displayed the most promising profile, with low nanomolar (102 nM {+/-} 2.28) activity and negligible host cell toxicity. This study offers new insights into the relative efficacy and safety of various anti-cryptosporidial compounds, highlighting their stage-specific effects on C. parvum and the consequential impacts on host cells. Identifying safe and effective anti-cryptosporidial agents contributes significantly to the One Health approach, emphasizing the importance of integrated strategies in controlling zoonotic diseases.

microbiology↗